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Readthrough acetylcholinesterase (AChE-R) and
regulated necrosis: pharmacological targets for the
regulation of ovarian functions?
J Blohberger1, L Kunz2, D Einwang1, U Berg3, D Berg3, SR Ojeda4, GA Dissen4, T Fröhlich5, GJ Arnold5, H Soreq6, H Lara7
and A Mayerhofer*,1
Proliferation, differentiation and death of ovarian cells ensure orderly functioning of the female gonad during the reproductive
phase, which ultimately ends with menopause in women. These processes are regulated by several mechanisms, including local
signaling via neurotransmitters. Previous studies showed that ovarian non-neuronal endocrine cells produce acetylcholine (ACh),
which likely acts as a trophic factor within the ovarian follicle and the corpus luteum via muscarinic ACh receptors. How its actions
are restricted was unknown. We identified enzymatically active acetylcholinesterase (AChE) in human ovarian follicular fluid as a
product of human granulosa cells. AChE breaks down ACh and thereby attenuates its trophic functions. Blockage of AChE by
huperzine A increased the trophic actions as seen in granulosa cells studies. Among ovarian AChE variants, the readthrough
isoform AChE-R was identified, which has further, non-enzymatic roles. AChE-R was found in follicular fluid, granulosa and theca
cells, as well as luteal cells, implying that such functions occur in vivo. A synthetic AChE-R peptide (ARP) was used to explore such
actions and induced in primary, cultured human granulosa cells a caspase-independent form of cell death with a distinct balloon-
like morphology and the release of lactate dehydrogenase. The RIPK1 inhibitor necrostatin-1 and the MLKL-blocker
necrosulfonamide significantly reduced this form of cell death. Thus a novel non-enzymatic function of AChE-R is to stimulate
RIPK1/MLKL-dependent regulated necrosis (necroptosis). The latter complements a cholinergic system in the ovary, which
determines life and death of ovarian cells. Necroptosis likely occurs in the primate ovary, as granulosa and luteal cells were
immunopositive for phospho-MLKL, and hence necroptosis may contribute to follicular atresia and luteolysis. The results suggest
that interference with the enzymatic activities of AChE and/or interference with necroptosis may be novel approaches to influence
ovarian functions.
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Necrosis was for a long time considered to be an unregulated
form of cell death that is beyond control. Apoptosis, by
contrast, was considered the only form of regulated cell death
that has roles not only in tissue homeostasis but also in
development and disease. This view has changed and
numerous morphologically and biochemically distinct forms
of cell death have been recognized by now.1,2 Programmed
necrosis, termed necroptosis, participates in a growing
number of diseases, for instance, ischemic injury in myocar-
dial infarction and stroke, ischemia–reperfusion injury, athero-
sclerosis, inflammatory bowel diseases, pancreatitis,
neurodegeneration, viral infection and other diseases.1,3–7
Necroptosis can be initiated by death receptors (e.g., tumor
necrosis factor (TNF) receptor 1 or Toll-like receptors (TLR))
by interferon receptor signaling and activation of the RNA-
responsive protein kinase PKR, the DNA receptor DAI (DNA-
dependent activator of interferon regulatory factors), aswell as
by other unknownmeans.5,8–10 It requires the kinase activity of
receptor-interacting serine/threonine-protein kinase 1 and 3
(RIPK1/3) and the formation of the necrosome. It involves
among others a pseudokinase (MLKL; mixed lineage kinase
domain like), which is phosphorylated by RIPK3 and then
executes programmed necrosis. A recent report showed that
in drug-induced liver injury the phosphorylated MLKL
(p-MLKL) can be traced by a monoclonal antibody11 in human
tissue. The execution involves the active integration of
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membranes (e.g., of mitochondria, lysosomes) and a balloon-
like swelling of the cells.12 Importantly, necroptosis can be
blocked by necrostatin-1 (Nec-1) or derivatives, and the MLKL
inhibitor necrosulfonamide (NSA). This may be a clinically
relevant approach to block cellular damage in diseases.5
Whether necroptosis has a role in physiological events is not
well established.
In the ovary, follicles grow, and then eventually reach the
ovulatory stage, in which the oocyte is released, or they
undergo atresia, a process that involves cell death of
granulosa cells (GCs) and of oocytes. Atresia is much more
frequent and indeed is the main fate of ovarian follicles. It
eventually results in the depletion of the ovarian pool of
follicles, and in human this inevitably leads to menopause.13,14
In small follicles of mice, there is evidence for not yet identified
non-apoptotic mechanisms, which are likely responsible for
atresia of primordial follicles.15 The ovarian cell death
processes of larger follicles, as far as known to date, can
involve apoptosis, autophagy, cornification and necrosis.16–21
The morphological description of necrotic GCs, together with
immune cells, that is, macrophages in ovarian follicles,17 is
strong evidence for a necrotic process, possibly necroptosis,
to occur.1,3–7,22
In the ovary, systemic and local signaling factors, that is,
hormones and growth factors, influence the fate of
follicles.13,23 Neurotransmitters may have a say, as well.24,25
Acetylcholine (ACh) stands out because it is synthesized in
the ovary by non-neuronal GCs, which form the main cellular
components of the follicle. The ovarian cholinergic system,
which includes muscarinic receptors, is part of a widespread
system of non-neuronal ACh production and local ACh
actions. These are found throughout the body and are best
examined in the immune system.26–28 The significance of the
ovarian cholinergic system is not clear yet. Previous studies
identified trophic, growth-promoting influences of ACh on GCs
via muscarinic receptors in bovine and human ovary and
derived cells.29 They include changes in the levels of
intracellular Ca2+, increased levels of a master transcription
factor (early growth response protein 1) and the activation of
several ion channels.30–34 Given an important trophic role of
ACh, its actions should be restricted spatially and temporarily.
Two esterases cleave and inactivate ACh, butyrylcholinester-
ase (BChE) and acetylcholinesterase (AChE). BChE was
described in proteomic studies as a component of follicular
fluid (FF),35,36 but little is known about ovarian AChE. Yet,
histochemical data suggested the expression by GCs in some
species.37 Several splice variants of AChE are known (e.g.,
AChE-E, -S, -R), which result in forms that differ in solubility
and subcellular localization.38,39 AChE-R furthermore exhibits
a unique C-terminal sequence, which is responsible for non-
enzymatic actions of this variant. It is involved in proliferation,
apoptosis and development of various cell types in different
organs, for example, brain and hematopoietic cells.40–46
To understand local regulation of ovarian functions by the
cholinergic system, we studied expression and functions of
AChE and BChE in human and in non-human primate ovary
and derived GCs. We found that AChE-R is an ovarian factor,
which can induce regulated necrosis (necroptosis) of GCs.We
also found that the cholinergic system and necroptosis of GCs
can be influenced pharmacologically and may represent novel
drug targets allowing intervention with basic ovarian pro-
cesses, namely proliferation, differentiation and cell death.
Results
Trophic ACh actions in human GCs are mediated by
muscarinic receptors and are limited by intrinsic AChE.
To study functional components of the ovarian ACh system,
we monitored cell confluence of cultured human GCs, that is,
the major cell population of large human ovarian follicles. An
increase in confluence due to cell spreading and/or cell
number was regarded as a trophic influence. Several
independent experiments showed a significant increase in
confluence after addition of ACh (10 μM; Figures 1a and b).
After 24 h, no difference between ACh-treated and the control
group was observed (Figure 1c), possibly because ACh
becomes degraded. Indeed, when the AChE inhibitor
huperzine A (HupA; 10 μM) was added to ACh, a significant
increase of confluence resulted after 12 and 24 h. This
suggests the presence of an intrinsic ACh degradation
system in the cultures, which can be blocked. AChE may
be produced by GCs or be present in the medium, which was
supplemented with fetal calf serum (FCS). Supporting the
prediction, the addition of HupA alone also increased
confluence, as seen after 12 h and 24 h and suggested that
endogenous ACh production and action are amenable for
manipulation. Blockage of the muscarinic ACh receptors of
GCs by atropine (1 μM) decreased confluence after 12 and
24 h. Simultaneous addition of ACh, HupA and atropine
resulted in unchanged confluence levels compared with
controls after 12 and 24 h. This indicates that the trophic
ACh effect relies on the activation of muscarinic receptors.
Nicotine (10 μM) was not able to induce trophic effects in
GCs. Thus ACh exerts trophic actions via muscarinic
receptors in human GCs. The use of HupA revealed that
AChE normally restricts trophic ACh actions. HupA imbal-
ances the cholinergic system of production and breakdown
events, and this action results in a net trophic action of ACh.
Cholinesterase activity in FF and human GC lysates.
Both AChE and BChE activity were detected in FFs from 15
in vitro fertilization patients (Figure 1d). AChE and BChE
activities accounted for nearly the same amounts of activity.
Western blotting revealed genuine AChE protein in FF
(Figure 1e). The western blotting was repeated with FFs
stemming from four different patients. Using an antibody
against AChE, we yielded a band of the expected 82-kDa
size. When the antibody was preadsorbed with the corre-
sponding blocking peptide, the band disappeared. In lysates
of cultured GCs, AChE activity was detected, whereas BChE
activity was very low (Figure 1f). The results indicate that
AChE is produced by human GCs, whereas BChE in FF may
mainly be derived from the circulation.
AChE isoforms in cultured human GCs. Reverse
transcription-PCR (RT-PCR) strategies followed by sequen-
cing allowed us to identify three AChE splice variants in
human GCs: the readthrough (R), erythrocyte (E) and
synaptic (S) AChE variant (Figures 2a–c). They were
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identified in GCs at different days of culture in six experiments
with independent GC preparations. AChE protein was
detected in GC lysates as well (four independent GC
preparations). An antiserum recognizing all AChE variants
and an antiserum specific for the R-variant were used for
western blotting studies. The antiserum against all AChE
variants revealed a band at the expected 82-kDa and this
staining was not observed upon preadsorption with AChE
(Figure 2d; two independent GC preparations). AChE-R
protein was detected as a single band (Figure 2e; six
independent GC preparations). Control blots in which the
specific antisera were omitted also revealed the specificity of
the results.
Expression of AChE isoforms in non-human primate and
human ovarian tissue. Immunohistochemical staining of
rhesus monkey ovarian sections with an antiserum against all
AChE variants revealed positive staining in FF and GCs of
preantral and antral follicles (Figures 3a and c). In pre-
adsorption experiments, this staining almost completely
disappeared (Figures 3b and d). In human ovarian tissue,
GCs and theca cells (TCs) of antral follicles were immuno-
reactive for AChE and preadsorption confirmed staining
specificity (Figures 3e and f). The AChE-R variant was
identified in GCs and TCs of human antral follicles by using
an antibody specific for this variant (Figure 3g). TCs showed
stronger staining for AChE-R than GCs. No staining was
found in the control experiment with serum only (Figure 3h).
In addition to follicles, cells of the human corpus luteum
specifically stained for AChE-R (Figure 3i). The staining of
theca–luteal cells was more intense than the staining of
granulosa–luteal cells and was not observed in control
experiments (using serum instead of the antiserum;
Figure 3j).
The AChE-R synthetic peptide ARP increases cell death
in cultured GCs. In contrast to the AChE-S and AChE-E, the
AChE-R is a soluble monomer and its specific C-terminal
peptide ARP has been shown to possess additional non-
enzymatic functions.41 To explore assumed non-enzymatic
effects in human GCs, we used a synthetic ARP peptide
(Figure 4). Live cell imaging performed over a 24-h time
period revealed massive cell death events in the ARP-treated
cells (50 ng/ml) compared with the untreated control group
(Figure 4a; Supplementary Data). A scrambled control
peptide (Scr; 50 ng/ml) and heat-inactivated ARP (ARPin;
50 ng/ml; 10 min, 95 °C) exhibited no bioactivity. Confluence
measurements furthermore underpinned this observation
Figure 1 Monitoring of the ACh system in human GCs and evidence for AChE in FFand cultured GCs. (a–c) Change in confluence (relative to control) of cultured human GCs
after 6, 12 and 24 h of treatment with different combinations of ACh (10 μM), HupA (10 μM), atropine (1 μM) and nicotine (10 μM). ACh initially shows a trophic effect on GCs but
is degraded during 24 h of stimulation. HupA blocks ACh-degradation and the trophic ACh-effect remains visible after 24 h. Atropine is able to block the ACh-mediated effect and
also decreases basal confluence change after 24 h. Nicotine was used as a control at 6 h and 24 h and shows no significant effect. Values are the mean± S.E.M. of n= 3
independent preparations of cells pooled from two to five patients each. For each stimulation, a parallel control experiment was performed. Different letters indicate significant
differences (Po0.05; analysis of variance). (d) AChE and BChE activity in FF, shown by the Ellman assay. Values are the mean± S.E.M. of n= 15 FFs of different patients (Total:
521± 45 mU/ml; BChE: 251± 23 mU/ml; AChE: 251± 26 mU/ml). (e) Identification of AChE protein in FF and a preadsorption western blotting experiment. Arrow indicates
expected mass of protein (82 kDa). (f) Lysates of cultured human GCs possess AChE activity and low BChE activity in the Ellman assay. Values are the mean± S.E.M. of n= 8
independent preparations of cells from two to five patients each (Total: 10± 3 mU/mg; BChE: 0.7± 0.3 mU/mg; AChE: 9± 2 mU/mg)
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(Figure 4b). Cell death events were first observed after
approximately 2–3 h upon the addition of ARP and continued
throughout a 24-h period. Many of the dying cells showed a
characteristic morphology upon ARP treatment. It involved
cytoplasmic ballooning (Figure 4c), which albeit at much
lower frequency could be found in control cells as well.
Lactate dehydrogenase (LDH) assays with 10 independent
preparations of cultured GCs were performed to detect LDH
release as measure for plasma membrane damage. The
results showed a significant increase after 5 h, indicating
cytotoxicity of ARP treatment compared with the control,
Scr and ARPin (Figure 5a). The pan-caspase inhibitor
Z-VAD-FMK (20 μM) did not prevent the ARP-dependent
increase in cytotoxicity seen in LDH measurements. Addition
of Z-VAD-FMK to GCs, however, blocked basally occurring
cell death, presumably apoptosis, which was observed in the
control group, in which the solvent dimethyl sulfoxide
(DMSO; 1‰) was tested (Figure 5b; seven independent
GC preparations). ARP stimulation did not change the
activities of caspase 3/7 over control groups (Figure 5c;
three independent GC preparations). The results indicate that
the type of cell death that is involved is not typical caspase-
dependent apoptosis. The RIPK1 inhibitor Nec-1 (20 μM)
significantly blocked the ARP-dependent increase in LDH
release when added to ARP-exposed GCs (Figure 5d;
10 independent GC preparations). This effect points to
necroptosis as cause for the increased number of cell deaths
by ARP stimulation. In the GC group treated with Nec-1
alone, a significantly reduced cytotoxicity became apparent,
indicating a basal level of necroptosis in GCs (Figure 5e; 10
independent GC preparations). Addition of NSA (0.5 μM), a
blocker of MLKL, effectively reduced necroptotic cell death,
Figure 2 AChE variants in humanGCs. (a) Simplified AChE gene structure with brackets indicating the position of PCR products. (b) Three possible 3′-AChE splice variants AChE-S,
AChE-R and AChE-E. (c) RT-PCR and sequencing showed that the AChE-S, AChE-R and AChE-E variant are present in humanGCs (hGC) at different days in culture. Water and RNA
controls were negative. (d) AChE protein was detectable in human GCs by using western blotting. Arrow indicates the expected size of protein (82 kDa). (e) Western blotting with an
antiserum specific for the AChE-R variant revealed the presence of this variant in human GCs. Arrow indicates the position of specific protein band. A serum control was negative
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indicated by its ability to inhibit ARP-induced cytotoxicity
(Figure 5f; 10 independent GC preparations). As in the case
of Nec-1, NSA significantly reduced cytotoxicity in GCs
compared with untreated control (Figure 5g), and this further
indicates that necroptosis is a form of cell death in GCs. As
Nec-1 is dissolved in ethanol and NSA in DMSO, we
excluded non-specific possible cytotoxic actions of the
corresponding solvents (ethanol (0.1‰) and DMSO (0.1‰))
using the LDH assay, (Figures 5d and f). Furthermore,
RIPK1, RIPK3 and MLKL, key proteins in the necroptosis
pathway, were identified in three GC preparations by using
western blotting (Figures 5h and i; for RT-PCR data, see
Supplementary Data). ARP, but not the control peptide,
increased the levels of p-MLKL after 5 h, which corresponds
to the time, when the cytotoxicity of ARP was confirmed
by LDH measurements (Figure 5i). This experiment was
repeated using three independent GC preparations
(Supplementary Data).
Detection of p-MLKL in non-human primate and human
ovarian tissue. We used a monoclonal antibody, which
was recently described11 and allows in human tissue
immunohistochemical identification of p-MLKL, that is, a
marker for necroptosis. The human corpus luteum showed
specific staining for p-MLKL (Figures 6a and b), while the
immunoglobulin G (IgG) control was negative (Figure 6c). In
rhesus monkey follicles, the GCs were immunoreactive for
p-MLKL (Figure 6d). The IgG control was devoid of staining
(Figure 6e).
Discussion
Several stimuli are known to initiate regulated necrotic cell
death,1,5,10 but to our knowledge, AChE-R has not been
described to be among them. AChE-R is one of the several
splice variants of AChE, which is responsible for enzymatic
ACh degradation. The results obtained in our study reveal that
via additional non-enzymatic mechanisms it induces RIPK1-/
MLKL-dependent regulated necrosis (necroptosis), that is, a
hitherto unrecognized form of cell death in primary human
ovarian cells.
AChE was previously linked to cell death.47,48 It appeared,
for example, to be involved in TNFalpha–induced apoptosis in
Hela cells, endothelial cell lines and primary rat aorta smooth
muscle cells. The prevalent isoform of AChE, expressed by
apoptotic cells, was AChE-S and pharmacological inhibition of
AChE prevented apoptosis.49 In neurons, an N-terminally
extended N-AChE-S variant was identified as being
apoptogenic.50 However, the splice variant AChE-R increased
apoptosis of male germ cells and spermatogenesis.51
Apoptosis was defined mainly by positive TUNEL staining,
which however may not be specific for apoptosis. The
mechanism(s) by which AChE-R impaired spermatogenesis
was thought to be related to, or mediated by, the known AChE-
R interaction partner, the scaffold protein RACK1 (receptor of
activated C kinase 1) and/or enolase-alpha.51
Using morphological observation, measurements of LDH
release and caspase 3/7-activation, the use of inactivated
ARP and the control peptide Scr, in conjunction with Nec-1,
Figure 3 AChE and the AChE-R variant in ovarian tissue. (a and c) In rhesus monkey, ovarian tissue FF and GCs are positive for AChE in an immunohistochemical staining.
(b and d) Preadsorption controls are nearly devoid of staining. (e) Immunohistochemistry using human ovarian sections shows positive staining for AChE in GCs and TCs of antral
follicles. (f) Preadsorption control shows no staining. (g) GCs and TCs in human antral follicles are positive for the AChE-R variant. (h) Serum control lacks staining. (i) Human
luteinzed GCs (LGCs) and luteinized TCs (LTCs) are positive for AChE-R. (j) Serum control lacks staining. Bars indicate 500 μm (a and b), 80 μm (c and d), 50 μm (e–h), 100 μm
(i) and 50 μm (j)
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NSA and a pan-caspase inhibitor, clearly link AChE-R to
regulated necrosis of human GCs, in vitro. Importantly, the
detection of p-MLKL in ovarian sections implicate that
necroptosis occurs in vivo in the primate ovary, in addition to
the well-examined apoptotic cell death. Regulated necrosis
(necroptosis) is being implicated in human diseases.1,5 Our
results indicate that necroptosis is an unrecognized form of
cell death of human ovarian cells and thus a part of ovarian
physiology, namely follicular atresia and luteolysis. This is in
line with reported necrotic cell death in Drosophila ovary52 and
necrosis of GCs in follicles of mammalian species.17
We do not know how AChE-R/ARP can induce necroptosis
in GCs. Based on previous studies, RACK1 and enolase51
may be involved, as may be TLRs or other death
receptors.53,54 GCs express TLR4,55 but neither lipopolysac-
charide, a ligand of TLR4, nor TNFalpha, did induce
necroptotic events in GCs (Supplementary Data). Levels of
reactive oxygen species (ROS)12 also did not change at least
during a 5-h time period of observation after addition of ARP
(see Supplementary Data). AChE-R has been called a stress
form of AChE, as its expression is increased upon oxidative
stress.46,56 It is under the control of microRNA (miRNA)-13257
that was elevated in exosomes of FFof growing bovine follicles
versus fully grown follicles.58 Ample evidence for oxidative
stress and ROS in follicles and human GCs has also been
provided,24 and our unpublished data revealed the presence
of miRNA in human GCs. Details remain to be studied.
Cultured human GCs resemble not only both GCs from the
large preovulatory follicle but also luteinizing GCs from the
corpus luteum. In both, the follicle and in the corpus luteum,
cell death events are crucial for ovarian physiology. Atresia of
many ovarian follicles allows the selection of a few ovulatory
Figure 4 ARP increases cell death in cultured human GCs. (a) Live cell imaging details of GCs treated with ARP (50 ng/ml), Scr (50 ng/ml) and heat-inactivated ARP (ARPin;
50 ng/ml). Note decreased number of cells after 24 h ARP treatment. (b) ARP (50 ng/ml) stimulation decreases confluence in human GCs compared with control group during
24 h. Values are the mean± S.E.M. of n= 3 independent preparations of cells from two to five patients each. (c) Characteristic morphology of ARP induced cell death at 0 and
16 h after ARP stimulation
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ones. Regression of the corpus luteum is necessary to allow
initiation of a new ovarian cycle. It is thought that apoptosis is a
major mechanism in luteal regression, that is, luteolysis.17,59
Indeed, in contrast to follicular atresia, apoptosis has been the
only described form of cell death in this ovarian compartment
to date.59,60 In follicles and the corpus luteum, a cholinergic
system has been implicated in local trophic actions.29,61 Our
cellular studies in GCs further support and extend this view, by
showing that AChE variants are important parts of this ovarian
system and via their enzymatic properties degrade ACh.
However, the ovarian cholinergic system has yet an additional
component: non-enzymatically acting AChE-R, which induces
Figure 5 Nec-1 and NSA block ARP-induced increase in cell death, while Z-VAD-FMK does not. (a) LDH cytotoxicity assay performed with cultured human GCs. ARP
(50 ng/ml) significantly increases cytotoxicity compared with control groups (Scr 50 ng/ml; ARPin 50 ng/ml; Po0.05; analysis of variance (ANOVA)). (b) Z-VAD-FMK (ZVF;
20 μM) does not block ARP-regulated increase in cytotoxicity. Treatment with ZVF only significantly decreases cytotoxicity compared with control (DMSO 1‰; Po0.05; ANOVA).
(c) No increased activity of caspase 3/7 was detected in ARP-treated cells compared with control groups (Po0.05; ANOVA). Values are the mean± S.E.M. of n= 3 independent
preparations of cells pooled from two to five patients each. (d) Nec-1 (20 μM) significantly blocks ARP-regulated increase in cytotoxitcity. Ethanol (EtOH; 0.1‰) has no effect on
ARP-dependent increase in cytotoxicity. (e) Treatment with Nec-1 causes significant lower cytotoxicity compared with control group (Po0.05, t-test). (f) NSA (0.5 μM) is able to
block ARP-dependent increase in cytotoxicity (Po0.05; t-test). DMSO (0.1‰) has no effect on ARP-dependent increase in cytotoxicity. (g) Treatment with NSA causes
significant lower cytotoxicity compared with control group (Po0.05, t-test). All values of LDH-assays are shown as mean± S.E.M. of n= 10 (except Z-VAD-FMK stimulation,
panel b, n= 7) independent preparations of cells from two to five patients each. (h) Identification of RIPK1 and RIPK3 protein in cultured human GCs by western blotting. Arrows
indicate the expected mass of protein (RIPK1: 76 kDa; RIPK3: 57 kDa; p-MLKL: 54 kDa). Serum control was negative. (i) Identification of MLKL and p-MLKL in cultured human
GCs by western blotting. ARP treatment for 5 h increased the levels of p-MLKL compared with control group, which was treated with the control peptide (Scr). Arrows point to the
expected mass of the proteins (MLKL 37 kDa; p-MLKL: 54 kDa). Different letters in a–g indicate statistically significant differences between the treatment groups
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necroptosis and thus complements the cholinergic system of
the ovary in an unexpected way.
What are the possible implications of these new insights?
We believe that both ovarian AChE and necroptosis could be
potential targets for pharmacological intervention. For exam-
ple, AChE-R levels in the human circulation increase with
age62 and the inhibition of cholinesterases is a widely used
approach in case of human Alzheimer’s disease.63 Could such
an approach also alter human ovarian functions? Could
specifically the trophic actions of ACh be enhanced and would
this reduce follicular atresia and/or increase the life span of the
corpus luteum? And is necroptosis occurring in GCs/luteal
cells, induced by AChE-R and presumably other factors,
‘treatable’with Nec-1 and NSA? This option nowopens up and
may be explored further.5 Follicular atresia, driven by apoptotic
and presumably necroptotic cell death, ultimately leads to the
depletion of the ovarian follicle pool and to menopause in
women.13,14,23 If the cholinergic system and necroptosis do
contribute significantly, it may be possible to use AChE
inhibitors and/or necroptosis inhibitors to interfere with the
depletion of the ovarian follicle pool during ageing and thus
possibly delay menopause.
Materials and Methods
Human GC isolation, culture and treatment. Human GCs were derived
from FF aspirates of IVF patients stimulated according to routine protocols.19,24,64–66
The local ethics committee of the University of Munich (Ludwig-Maximilian-
University (LMU)) approved of the project and the use of human samples (project
323-05). Patients gave their written agreement and samples were anonymized.
Aspirates from two to five patients were pooled for GCs preparation, and GCs were
purified according to a method described.67 It involves a cell strainer (40 μm; BD,
Franklin Lakes, NJ, USA) for filtration of the aspirates. GCs, which remained in cell
strainer, were retrieved by washing with Dulbecco’s modified Eagle’s medium
(DMEM)/Ham’s F12 Medium (PAA, Cölbe, Germany). The filtrate was centrifuged
and the supernatant (i.e., cell-free FF) was frozen at − 20 °C until further use.
Remaining cell aggregates in the acquired cell suspension were suspended
mechanically by using a 0.9-mm cannula. Washed cells were re-suspended and
cultured in DMEM/Ham’s F12 medium supplemented with penicillin (100 U/ml),
streptomycin (100 μg/ml) and 10% FCS (all from PAA).19,64–66 Primary GCs were
cultured for up to 6 days. Except for studies done immediately after isolation (day 0),
cells were rinsed on day 1 of culture with fresh medium to remove non-adherent and
dead cells. For all experiments, DMEM/Ham’s F12 medium without supplements
was used, except for confluence studies, where 5% FCS was added to the
medium. ACh (Life Technologies, Carlsbad, CA, USA), AChE-R peptide ARP
(1-GMQGPAGSGWEEGSGSPPGVTPLFSP-2642), a nonsense scrambled peptide
(Scr; both synthesized at the GeneCenter, LMU Munich), atropine (Sigma-Aldrich,
St Louis, MO, USA), HupA (Sigma-Aldrich), Nec-1 (Santa Cruz Biotechnology,
Dallas, TX, USA), NSA (Tocris Bioscience, Bristol, UK) and Z-VAD-FMK (R&D
Systems, Minneapolis, MN, USA) were used in several experiments.
Confluence measurement. GCs were cultured up to 4 days and confluence
of GCs was monitored for 24 h by taking time-lapse pictures every 10 min using a
live cell analyzer (Peqlab, Erlangen, Germany). For each stimulation protocol,
respective control cells were observed simultaneously. The software of the live cell
analyzer determined confluence values.
Ellman assay. This assay is based on a previously described method68,69 with
some alterations. 5,5-Dithiobis-2-nitrobenzoic acid (final concentration 0.6 mM),
acetylthiocholine iodide (final concentration 1.5 mM), BW284c51 (final concentration
0.1 mM), tetra-isopropyl pyrophosphoramide (final concentration 0.1 mM) and AChE
from Electrophorus electricus were purchased from Sigma-Aldrich. BW284c51 was
used for AChE inhibition and tetra-isopropyl pyrophosphoramide for BChE inhibition.
The assay was performed in 96-well plates with a total volume of 250 μl. Change in
absorbance at 405 nm was measured in a microplate reader (BMG labtech,
Ortenberg, Germany) for 8 min. FFs were used in a final dilution of 1/320. Lysates
of GCs cells cultured in serum-free medium were frozen at − 20 °C, thawed and
washed two times in Ellman buffer and used in a 1/8 dilution for activity
measurements. Absolute activity values were determined by comparing with an
AChE standard (Electrophorus electricus).
Western blotting. Western blotting24 was performed with a goat antiserum
raised against all human AChE variants (Santa Cruz Biotechnology) and the
corresponding blocking peptide (Santa Cruz Biotechnology). In addition, a rabbit
antiserum raised against the human AChE-R C-terminus was used.41 For detection
of necroptosis-related proteins, we used antiserum against RIPK1 (Sigma-Aldrich),
and monoclonal antibodies against RIPK3 (Sigma-Aldrich), against MLKL (Sigma-
Aldrich) and against p-MLKL (Abcam, Cambridge, UK). Densities of the bands were
evaluated using ImageJ (National Institutes of Health, Bethesda, MD, USA) as
described.24
Reverse transcription-PCR. Total RNA of cultured cells was isolated using
the RNeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription was
performed with 400 ng RNA using random hexamer primers and Superscript II (Life
Technologies). RT-PCR was arranged with different oligomer primers70 (Table 1).
Figure 6 p-MLKL in primate ovarian tissue. (a and b) Cells in human corpus luteum (CL) are positive for p-MLKL. (c) IgG control lacks staining. (d) GCs in antral follicles of
rhesus monkeys show positive staining for p-MLKL. (e) IgG control lacks staining. Bars indicate 100 μm (a) and 40 μm (b–e)
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PCR products were analyzed by using agarose gel electrophoresis with ethidium
bromide or Midori Green (Nippon Genetics Europe GmbH, Düren, Germany)
staining. All products were confirmed by sequencing.24
Immunohistochemistry. Sections of human ovaries derived from a local
collection at Anatomy III, Cell Biology (Munich, Germany) and sections of ovaries
from rhesus macaques (Macaca mulatta, age 5–6 years), derived from the
Oregon National Primate Research Center (Beaverton, OR, USA), were used for
immunohistochemistry. The collection of monkey tissues had been approved by the
Oregon National Primate Research Center Institutional Animal Care and Use
Committee. Immunohistochemistry was performed with the same antisera used for
western blotting. Tissue samples and immunohistochemistry were described
previously.24,66 In brief, after removal of paraffin, antigen retrieval and blocking of
endogeous peroxidase activity, the tissue was incubated in 5% appropriate serum,
diluted in phosphate-buffered saline. Antiserum incubation was done overnight at
4 °C. The antiserum against all AChE variants was diluted 1 : 100, the antiserum
against AChE-R 1 : 200 and the antibody against p-MLKL 1 : 50. Incubation with a
biotinylated secondary antibody (1 : 500 dilution; Dianova, Hamburg, Germany) for
2 h at room temperature followed. A Vectastain ABC Kit (Vector Laboratories,
Burlingame, CA, USA) and a 3,3′-diaminobenzidine tablet set (Sigma-Aldrich) were
used for the final staining procedure. Slides were covered by using Entellan (Merck
Millipore, Billerica, MA, USA). Controls included incubation with serum or IgG
instead of the first antiserum or antibody. In case of AChE, incubation with antigen-
peptide preadsorbed antiserum was employed.
Live cell imaging. GCs were seeded in dishes with glass bottom (Ibidi,
Munich, Germany) and observed on a light microscope (Carl Zeiss, Oberkochen,
Germany) for 24 h after stimulation in a heated incubation chamber with constant
humidity and CO2 concentration (Ibidi, Munich, Germany). A total of 100–200 cells
were monitored in each experiment. Pictures were taken with a digital microscope
camera (Jenoptik, Jena, Germany) and analyzed with the Micro-Manager software
(www.micro-manager.org). By counting cell number at 0 h and cell number of dead
cells at 24 h, the percentage of cell death was determined.
LDH assay. Isolated GCs were seeded in 96-well plates for analyzing
cytotoxicity of stimulants with a LDH cytotoxicity assay kit (Thermo Scientific,
Waltham, MA, USA). This assay measures LDH in the cell supernatant as an
indicator of damaged cell membranes. Absorbance after 5-h stimulation (between
day 2 and 5 of culture) was measured at 492 nm and 690 nm (background) in
triplicates with a microplate reader (BMG labtech).
Caspase assay. Caspase 3/7 activity in GCs on 96-well plates was determined
by using a caspase-glo assay system (Promega, Fitchburg, WI, USA).
Luminescence after 5-h stimulation (between day 3 and day 5 of culture) was
measured in triplicates on a microplate reader (BMG labtech).
Statistics. Statistical analyses were done using Prism 5 (GraphPad Software,
San Diego, CA, USA). A one-way ANOVA followed by the Newman–Keuls post-test
(Po0.05) was performed for confluence measurements and results of cell imaging.
Activity measurements were analyzed by column statistics. For caspase 3/7 assay
and LDH assays with ARP stimulation, a repeated-measures ANOVA, followed by
the Newman–Keuls post-test (Po0.05) was used. For the LDH assays with Nec-1
and NSA compared with control only, an unpaired t-test was performed (Po0.05).
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